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Key Points
• NOD-specific Sirpa polymor-
phism is the genetic determi-
nant of highly efficient xeno-
graft activity in NOD-based
immunodeficient mouse mod-
els.
Current mouse lines efficient for human cell xenotransplantation are backcrossed into
NOD mice to introduce its multiple immunodeficient phenotypes. Our positional
genetic study has located the NOD-specific polymorphic Sirpa as a molecule respon-
sible for its high xenograft efficiency: it recognizes human CD47 and the resultant
signaling may cause NOD macrophages not to engulf human grafts. In the present
study, we established C57BL/6.Rag2nullIl2rgnull mice harboring NOD-Sirpa (BRGS). BRGS
mice engrafted human hematopoiesis with an efficiency that was equal to or even better
than that of the NOD.Rag1nullIl2rgnull strain, one of the best xenograft models. Conse-
quently, BRGS mice are free from other NOD-related abnormalities; for example, they
have normalized C5 function that enables the evaluation of complement-dependent cytotoxicity of antibodies against human grafts
in the humanized mouse model. Our data show that efficient human cell engraftment found in NOD-based models is mounted solely
by their polymorphic Sirpa. The simplified BRGS line should be very useful in future studies of human stem cell biology. (Blood.
2013;121(8):1316-1325)
Introduction
Immunodeficient mice are widely used to reconstitute human
hematopoiesis by xenotransplantation of hematopoietic stem cells
(HSCs).1,2 This “humanized” mouse model provides a powerful
tool with which to evaluate the biologic properties of human HSCs
and progenitors in vivo.3,4 Such xenotransplantation systems have
also been used to study human cancer stem cells.5-8
Elimination of the lymphoid system is the first step to achieving
reconstitution of human hematopoiesis. To deplete T and B cells,
the scid mutation in the Prkdc gene9-11 or disruption of the
recombination activating gene 1 or 2 (Rag1 and Rag2)12,13 has been
introduced into various mouse strains. In addition, to deplete
natural killer (NK) cells or their functions, the IL-2 receptor
common  chain subunit (Il2rg)14-16 or beta-2-microglobulin
(B2m)17-19 is disrupted.
However, depletion of lymphoid cells is not sufficient and it has
been shown empirically that additional strain-specific factors
modulate human hematopoietic engraftment in the xenotransplanta-
tion setting. For example, within the SCID strain, the SCID with
the NOD background was the gold standard for the xenotransplan-
tation assay based on its high efficiency.11 In fact, recent studies
have shown that among the lymphoid-depleted mouse strains, the
NOD-scid Il2rgnull (NSG/NOG)14,15 and NOD.Rag1nullIl2rgnull
(NOD-RG)20 strains are the most efficient; the BALB/c.Rag2nullIl2rgnull
(BALB-RG) strain is the next efficient21,22; and the C57BL/6 strains
with scid,23 Rag2null, Rag2nullB2mnull, Rag2nullPrfnull,24 or Rag2nullJak3null25
mutations are unable to reconstitute human hematopoiesis. The
NOD strain has multiple immune deficiencies, including defects of
appropriate regulation of the T-lymphocyte repertoire, antigen
presenting cell function, NK cell function,26and hemolytic comple-
ment (C5) and cytokine production from macrophages,27 and these
abnormalities are presumed to collaborate to cause the develop-
ment of autoimmune diabetes and hemolytic anemia.26,28 To
establish xenotransplantation models, lymphoid-depleted strains
have been backcrossed into the NOD/ShiLt–inbred strain multiple
times to introduce such numerous NOD-specific abnormalities.14,15
However, it was unknown whether we could select a genetic
determinant(s) specially required to achieve the NOD-specific high
engraftment capability for human cells.
Previously, we used positional genetics to characterize the
molecular basis for this capability in the NOD strain by measuring
the ability of mouse BM stromal layers to support hematopoietic
long-term culture-initiating cell activity (LTC-IC) in vitro and
identified the strain differences as the polymorphism of the Sirpa
gene located within the insulin-dependent diabetes (Idd-13) locus.24
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Stroma cells from the NOD BM supports LTC-IC of human cells,
but those from C57BL/6 could not. Enforced expression of the
NOD-type SIRPA enabled C57BL/6 stroma cells to support human
LTC-IC.24 This in vitro finding is also applicable to the in vivo
setting, as shown by another study in which a human SIRPA BAC
transgene introduced into Rag2nullIl2rgnull mice on a mixed 129;
BALB/c background significantly improved the efficiency of
human hematopoietic engraftment.29
SIRPA is a transmembrane protein that contains 3 Ig-like
domains within the extracellular region. It is expressed in macro-
phages, myeloid cells, and neurons, and interacts with its ligand
CD47 through its respective IgV-like domains, where the NOD
strain has specific polymorphism. CD47 is a member of the Ig
superfamily that is ubiquitously expressed in hematopoietic and
nonhematopoietic cells. The cytoplasmic region of SIRPA has
immunoreceptor tyrosine–based inhibitory motifs, and binding
cell-surface CD47 with SIRPA on macrophages provokes inhibi-
tory signals through phosphorylation of these inhibitory motifs of
SIRPA,30 preventing their phagocytic activity.31-33 A recent study
also showed that transgenic expression of mouse CD47 into
CD34CD38 human fetal liver cells significantly enhanced the
human cell engraftment into BALB-RG mice.34 Based on these
data, the binding of NOD-SIRPA with human CD47 might produce
signals for mouse macrophages not to engulf human HSCs, which
presumably makes the strain permissive for human HSC
engraftment.24
The most important question was whether the NOD-specific
highly efficient human cell engraftment in vivo could be explained
solely by the NOD-Sirpa polymorphism. In the present study, we
established a C57BL/6.Rag2nullIl2rgnull (C57BL/6-RG) mouse line
harboring the NOD-type Sirpa. Our data show clearly that replace-
ment of the C57BL/6-type Sirpa with the NOD-type Sirpa is
sufficient for the C57BL/6-RG strain to be endowed with the
xenotransplantation capability that is at least equal to NOD-RG
mice. Therefore, we successfully segregated the genetic abnormal-
ity responsible for efficient human cell engraftment from mul-
tiple genetic abnormalities in the NOD strain. The simplified
humanized mouse system established by the new C57BL/
6.Rag2nullIl2rgnullNOD-Sirpa (BRGS) strain should be very useful
in improving xenotransplantation strategies in future studies of
human cell biology.
Methods
Mice
C57BL/6, C57BL/6.NOD-Idd13, NOD, NOD.CB17-Prkdcscid (NOD-scid),
and NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/Sz (NOD-RG) mice were purchased
from the Jackson Laboratory; C57BL/6.Rag2tm1FwaIl2rgtm1Wjl (C57BL/6-RG)
mice were purchased from Taconic. All mice were bred and maintained in
individual ventilated cages at the Kyushu University Animal Facility and
fed with autoclaved food and water. BRGS mice were generated by
breeding C57BL/6-RG and C57BL/6.NOD-Idd13 mice and backcrossed
with C57BL/6-RG mice. Rag2 gene and Sirpa gene are located on
chromosome 2 with 17.1 cM. First, we repeated the breeding of C57BL/
6-RG and C57BL/6.NOD-Idd13 mice, and after 10 breedings, we obtained
the recombination between the Rag2 and the SirpaNOD loci by chromo-
somal crossover. This was examined by genotyping by the microsatellite
markers D2Mit447 and D2Mit338, which are 0.63 cM apart on chromo-
some 2, during interbreeding. In addition, Sirpa, Rag2, and Il2rg were
genetically typed by PCR and direct sequencing. In C57BL/6.NOD-
(D2Mit447-D2Mit338) Rag2nullIl2rgnull mice, the region between D2Mit447
and D2Mit338 contains 33 genes, including Sirpa, but Sirpa is the only gene
within the Idd13 locus that is expressed in BM stromal cells and
macrophages and had coding sequence polymorphism between the NOD
and other strains.24 Therefore, we refer to our established mouse line as
BRGS herein. Sequences of the oligonucleotide primers used are provided
in supplemental Table 1 (available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). All experiments
were conducted following the guidelines of the institutional animal
committee of Kyushu University.
Binding affinity of mouse macrophages to human CD47-Fc
Mouse macrophages were obtained by peritoneal lavage. Cells were stained
with purified anti–mouse Sirpa (P84; BD Biosciences) conjugated with PE
and anti–mouse CD11b (3A33; Beckman Coulter) conjugated with FITC.
CD11bSIRPA cells were defined as mature macrophages. The binding
between SIRPA and CD47 was assessed by staining with biotinylated
human CD47-Fc conjugated with streptavidin-allophycocyanin (APC),35
and analyzed with a FACSAria III cell sorter (BD Biosciences).
In vitro mouse macrophage phagocytosis assays for human
hematopoietic stem cells
Phagocytic activity of mouse macrophages against the human CD34CD38
population that contains the majority of human HSCs was evaluated
in vitro, as described previously.36 In brief, mouse peritoneal-derived
macrophages were incubated at 1.0  104 cells in 200 L of RPMI
1640 medium in Falcon culture tubes (2058; BD Biosciences). Cells
were opsonized with CD34 antibody (sc-19621; Santa Cruz Biotechnol-
ogy), incubated with mouse IFN- (100 ng/mL; R&D Systems) for
24 hours, and then lipopolysaccharide (0.3 g/L) for 1 hour. Human
cord blood (CB) HSCs were then added to the tubes. Two hours after
coincubation with macrophages and target cells, the phagocytic index was
calculated using the following formula: phagocytic index  number of
ingested cells/(number of macrophages/100). At least 200 macrophages
were counted by a blinded observer.
Sensitivity of BRGS mice to irradiation
Cohorts of BRGS mice were exposed to varying doses of the whole-body
irradiation from a 137Cs -irradiator. The mice were examined daily and
euthanized when moribund. Surviving mice were euthanized at 8 weeks
after irradiation. NOG/NSG mice are highly radiosensitive because of the
scid mutation. To examine the radiosensitivity of BRGS mice, 6- to
10-week-old BRGS mice were irradiated with 550-670 cGy, and monitored
for 8 weeks. Early deaths were observed in the mouse group irradiated
with more than 620 cGy, whereas those irradiated with 550-580 cGy
survived at the end of 8 weeks. Based on these data, we irradiated
BRGS mice at 580 cGy in all xenotransplantation experiments. The
irradiation doses for experiments with NOD-RG (420 cGy) and C57BL/
6-RG (670 cGy) were decided by radiosensitivity experiments.
Transplantation of human HSCs into mice
CB cells were collected during normal full-term deliveries after obtain-
ing informed consent in accordance with the Declaration of Helsinki
(provided by the Kyushu Block Red Cross Blood Center, Japan Red
Cross Society). Mononuclear cells were separated by Ficoll-Hypaque
density-gradient centrifugation. Lineage-depleted CB cells were obtained
magnetically using a lineage cell depletion kit (Miltenyi Biotec). A total of
5  103 CD34CD38 cells were injected intrafemorally into mice. Within
an individual experiment, mice of each strain received CD34CD38 cells
purified from the same mixture of CB cells from multiple donors. After
transplantation, mice were given sterile water containing prophylactic
enrofloxacin (Baytril; Bayer HealthCare). Mice were killed 8, 16, or
24 weeks after transplantation.
Antibodies, cell staining, and sorting
For the analyses of mouse T, B, and NK cells, mouse peripheral blood cells
were stained with PE-conjugated anti-CD3 (145-2C11), FITC-conjugated
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anti-CD19 (1D3), APC-conjugated anti-NK1.1 (PK136; BD Biosciences),
and Pacific Blue–conjugated anti–Gr-1 (RB6-8C5; BioLegend). Sorting of
CD34CD38 subfractions was accomplished by staining lineage-depleted
CB cells with FITC-conjugated anti-CD34 (581/CD34) and PE-conjugated
anti-CD38 (HIT2; BD Biosciences). For analysis and sorting of human cells
in the immunodeficient mice, FITC-conjugated anti-CD4 (RPA-T4), CD33
(HIM3-4), CD41a (HIP8), TCR  (WT31), TCR 	 (11F2), Ig
 L chain
(JDC-12), Ig L chain (G20-193; BD Biosciences), anti-CD10 (SS2/36;
Dako), PE-conjugated anti-CD8 (RPA-T8), CD20 (2H7), NKp46 (9E2; BD
Biosciences), CD235a (JC159; Dako), PE-Cy7–conjugated anti-CD3 (SK7;
BD Biosciences), CD19 (HIB19; BioLegend), APC-conjugated anti-CD45
(J33; Beckman Coulter), and PaB-conjugated anti–mouse CD45 (30-F11;
BioLegend) monoclonal antibodies were used in addition to the antibodies
described in the preceding paragraph. Nonviable cells were excluded by
propidium iodide staining. The cells were analyzed and sorted with a
FACSAria cell sorter (BD Biosciences).
Complement-dependent hemolytic activity
To estimate the serum complement activity of mice, the peripheral blood of
mice were collected in 1.5-mL tubes and allowed to stand at room
temperature for 1 hour. The serum was collected after centrifugation of the
blood at 200g for 15 minutes at 4°C and stored 80°C until use. The
mixtures of each diluted sera of mice, 3.75  106 erythrocytes of sheep and
2.5g of zymosan (Imgenex) were incubated 10 hours at 37°C. After
incubation, the absorbance of each sample at 415 nm was measured.
In vivo antibody treatment in a disseminated lymphoma
xenograft model
A total of 8  105 Raji cells (Burkitt lymphoma cell line; American Type
Culture Collection) were injected into BRGS or NOD-RG mice (6-10 weeks
of age) via the tail vein. Raji cells proliferated predominantly in the BM.
Ten days after injection, these mice were IP injected daily with 200 g of
rituximab or mouse IgG2a control for 1 week and then BM cells were
collected and analyzed with the FACSAria III.
Statistical analysis
Data are presented as means  SD. The significance of the differences
between groups was determined via the Student t test. For comparison of
complement-dependent hemolytic activity among the mouse strains,
repeated-measures ANOVA was performed.
Results
Establishment of the BRGS mouse
The BRGS mouse line was established by breeding the C57BL/
6-RG with the C57BL/6.NOD-Idd13 mouse that is congenic for
NOD-derived Idd13 locus within which the Sirpa is the only gene
that is polymorphic and is expressed in the BM stromal cells.24
BRGS mice were all born healthy and displayed good fertility.
They showed a median life span of 65 weeks without the
development of lymphoma that usually occurs in the NOD-scid
strain after the age of 5 months.11
As shown in Figure 1A, BRGS mice had normal levels of
hemoglobin and platelets, but a low number of leukocytes. This is
because of the lack of CD3 T cells, CD19 B cells, and NK1.1
NK cells (Figure 1B). IP macrophages from either C57BL/6-RG,
BRGS or NOD-RG mice were evaluated for the binding to human
CD47 on FACS. CD11b peritoneal macrophages strongly ex-
pressed SIRPA in all of these strains. As shown in Figure 1C, both
macrophages from the BRGS and those from the NOD-RG strain
bound to the human CD47-Fc protein, whereas those from the
Figure 1. BRGS mice lack lymphocytes and SIRPA recognizes human CD47-Fc. (A) Frequencies of blood leukocytes, erythrocytes, hemoglobin, and platelets in BRGS
mice. Leukocyte counts in BRGS (2.69  1.01  103/L) and NOD-RG mice (2.23  0.7  103/L) are significantly decreased compared with that in C57BL/6 mice
(9.6  0.32  103/L). BRGS mice have normal erythrocyte (9.63  0.63  106/L), hemoglobin (14.0  0.6 g/dL), and platelet (8.7  2.0  105/L) counts. (B) Represen-
tative FACS plots of blood in C57BL/6 and BRGS mice. BRGS mice lacked T, B, and NK cells. (C) Binding activity of human CD47-Fc to SIRPA expressed in peritoneal
macrophages derived from C57BL/6-RG, BRGS, or NOD-RG mice. Macrophages from BRGS and NOD-RG mice, but not those from C57BL/6-RG mice, were stained with
human CD47-Fc on FACS. (D) Phagocytosis assay of C57BL/6-RG, BRGS, or NOD-RG macrophages against human CD34CD38 CB HSCs (n  3). The phagocytic index
was determined as the number of engulfed cells per 100 macrophages. Bars indicate mean SD.
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C57BL/6 strain did not, confirming that BRGS mice have the
NOD-type SIRPA that can bind to human CD47. Consistent
with these binding data, when macrophages of each strain were
cultured with human CD34CD38 cells, macrophages from
C57BL/6-RG mice, but not those from BRGS or NOD-RG mice,
actively engulfed human CD34CD38 cells, as shown by the
significant elevation of the phagocytic index in the C57BL/6-RG
mice (Figure 1D).
BRGS mice are capable of multilineage reconstitution of
human hematopoiesis with efficiency at least equal to that of
NOD-RG mice
A recent study has shown that intrafemoral injection is more
efficient than IV injection in the xenotransplantation setting.37
We used intrafemoral injection into adult mice in the present
study because our preliminary data also showed that human cell
chimerisms of adult BRGS by intrafemoral injection was
significantly better than those with IV injection (data not shown).
We transplanted 5  103 CD34CD38 human CB cells intrafemo-
rally into C57BL/6-RG, BRGS or NOD-RG mice at the age of 6-8
weeks. Before transplantation, C57BL/6-RG, BRGS, and NOD-RG
mice were irradiated with 670, 580, and 420 cGy, respectively.
Each dose was set by irradiation tolerance experiments (see the
Methods).
At 8 weeks after transplantation, human CD45 cells were not
detectable in C57BL/6-RG mice (Figure 2A). Both BRGS and
NOD-RG showed successful reconstitution and their average
frequencies of human CD45 cells were 59.9% and 55.8%,
respectively. Recent studies have shown that in the NSG strain,15
female recipients better support the reconstitution of human
hematopoiesis, although the underlying mechanism for this re-
mains unclear.38,39 As shown in Figure 2A, NOD-RG and BRGS
female mice showed equally excellent human CD45 reconstitu-
tion at approximately 70% chimerism. NOD-RG male mice,
however, showed significantly poor reconstitution (16.6% of
human cell chimerism on average) compared with NOD-RG
female mice. In contrast, the percentages of human cell chimerisms
in BRGS male mice (approximately 45%) were only slightly lower
than those in BRGS female mice and, as a result, BRGS male mice
showed significantly better engraftment compared with NOD-RG
male mice.
In the BM, the percentages of CD19 B cells, CD33 myeloid
cells, and CD34CD38 cells that contain the majority of human
HSCs were almost equal between the BRGS and the NOD-RG
strains irrespective of sex (Figure 2B). Representative FACS plots
at 8 weeks after injection are shown in Figure 3A. In the spleen,
small numbers of CD3 T cells and CD3NKp46 NK cells, as
well as CD41 megakaryocytes and CD235a erythrocytes, were
found in both BRGS and NOD-RG mice (Figure 3A) and there was
no significant difference in the percentages of these cells between
the 2 strains regardless of sex. The majority of human cells in the
spleen were CD19 B cells (Figure 3B). Although BM human
Figure 2. BRGS mice show efficient engraftment of
human HSCs comparable to NOD-RG mice. In the
BM, human HSC engraftment was examined by flow
cytometric analysis 8 weeks after transplantation. C57BL/
6-RG mice (f; n  5), female BRGS mice (F; n  17),
male BRGS mice (E; n  12), female NOD-RG mice
(Œ; n  13), and male NOD-RG mice (‚; n  5) mice
were analyzed. (A) Both BRGS and NOD-RG female
mice showed excellent human CD45 reconstitution.
BRGS male mice showed significantly better engraftment
compared with NOD-RG male mice. (B) Frequencies of
CD19 B cells, CD33 myeloid cells, and CD34CD38
HSCs in BRGS and NOD-RG mice.
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CD19 cells were mainly CD10CD20 immature B cells, the
majority (approximately 90%) of human spleen CD19 cells were
CD10CD20 mature B cells (data not shown). Thymic T cells
were found in both the BRGS and NOD-RG strains, and the
majority of human CD3 T cells in the thymus were CD4CD8
immature T cells (Figure 3A,C).
Figure 4 shows the analysis of reconstitution of human HSCs at
16 weeks after transplantation. In this analysis, we used only
female BRGS and NOD-RG mice. In the BM, both BRGS and
NOD-RG mice showed sustained human cell engraftment and the
frequencies of human CD45 cells were 64.4% and 51.1% in
average, respectively, which were comparable to their levels at
8 weeks after transplantation. The percentages of CD33 myeloid
cells, CD19 B cells, and CD34CD38 HSCs were comparable
to those at 8 weeks after transplantation (Figure 4A).
In the thymus, the percentage of CD3 T cells was increased up
to approximately 80% and approximately 60% in the BRGS and
NOD-RG strains, respectively. In addition to CD4CD8 thymic
precursors, both CD4 and CD8 single-positive T cells were
present and expressed surface TCR- or TCR-	, suggesting that
human T-cell maturation occurs in the BRGS thymus, as has been
shown previously in the NOG, NSG, and NOD-RG mouse
lines14-16,20 (Figure 4B). The number of CD20 mature B cells in
the spleen was increased and they expressed surface Ig light chain

/, reflecting their normal maturation (Figure 4C).
The BRGS mouse maintains self-renewal of human HSCs in
the long term
Figure 5A shows the changes in human cell chimerism in female
BRGS mice in the long term. The frequency of human CD45 cells
was maintained at a high level at least until 24 weeks after
transplantation. B-cell frequencies gradually declined, but human
myeloid, T, and NK cells progressively increased after engraftment
(Figure 5B). The delayed reconstitution of these lineages of human
cells has also been reported in studies using NSG mice.40,41
Figure 5C shows the results of the serial transplantation
analysis. After confirmation of human cell engraftment at 8 weeks
after the first transplantation, 1  106 human CD45 cells were
purified from primary BRGS recipients. These cells were trans-
planted into irradiated secondary BRGS recipients by intrafemoral
injection and tested for engraftment after another 8 weeks. Four of
6 secondary BRGS recipients showed multilineage engraftment of
human CD33, CD19, and CD3 cells (Figure 5C). These data
strongly suggest that BRGS mice can support long-term reconstitu-
tion and self-renewal of human HSCs.
The BRGS mouse is useful for experiments using CDC of
antibodies in the xenotransplantation setting
One of the problems in NOD-based xenograft models is that the
cytotoxic activities of antibodies are unable to be evaluated in vivo
Figure 3. Multilineage human HSC reconstitution in BRGS mice. (A) Representative FACS plots at 8 weeks after transplantation in the BM, spleen, and thymus.
(B) Human hematopoietic reconstitution in the spleens of BRGS and NOD-RG recipients (F: BRGS female; E: BRGS male; Œ: NOD-RG female; ‚: NOD-RG male).
There were no significant differences in the percentages of human CD45 cells and human CD19 B cells between these mice. (C) Human hematopoietic reconstitution
in the thymi of BRGS and NOD-RG recipients. There were no significant differences in the percentages of human CD45 cells and human CD3 T cells between these
mice. Symbols are as in panel B.
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in humanized mice. First, antibody-dependent cell-mediated cyto-
toxicity (ADCC) does not operate efficiently in xenotransplantation
experiments because these strains of mice are deficient in NK cells,
the major player for ADCC. In addition, immunodeficient pheno-
types of the NOD strain include complement-dependent hemolytic
activity due to a deficiency of C5,42 which is essential for
antibodies to exert complement-dependent cytotoxicity (CDC). All
NOD-based immunodeficient strains have this abnormality, whereas
the BRGS strain does not because it has a C57BL/6 background
except for the NOD-type SIRPA. We tested CDC activity in
C57BL/6-based strains, including the C57BL/6, C57BL/6-RG, and
BRGS mice, and in NOD-based strains such as NOD, NOD-scid,
and NOD-RG. As shown in Figure 6, sera from all of the
C57BL/6-based strains, including the BRGS strain, showed CDC
activities on sheep RBCs, whereas this was not found in any of
NOD-based strains. There were no significant differences in CDC
activities among the C57BL/6, C57BL/6-RG, and BRGS strains.
To determine whether BRGS mice had restored CDC in vivo,
8  105 cells of Raji, a Burkitt lymphoma cell line expressing
human CD45, was injected into BRGS or NOD-RG mice. Ten days
after transplantation, either rituximab, an anti-CD20 antibody that
has both CDC and ADCC activities, or a control IgG2a antibody
was administered IP for 7 days (Figure 7A) and the effect of
antibody injection on elimination of Raji cells was evaluated.
Representative results are shown in Figure 7B. In mice injected
with control IgG2a, Raji cells rapidly proliferated up to approxi-
mately 90% in the BM of both BRGS and NOD-RG mice. In
contrast, by injection of rituximab, percentages of human CD45
Raji cells were significantly decreased in BRGS mice (15.1%),
whereas the percentages of human CD45 cells in NOD-RG mice
were only slightly reduced by rituximab treatment (79.2%).
Representative FACS data are shown in Figure 7C. These data
clearly show that the CDC activity of antibodies was able to
operate in the BRGS strain.
Discussion
The NOD/ShiLt inbred mouse strain, which was originally devel-
oped by selecting cataract-prone strains,27 exhibits susceptibility to
the spontaneous development of autoimmune insulin-dependent
diabetes mellitus (IDDM) and many other autoimmune disorders.
The susceptibility to IDDM is polygenic and genetic loci associ-
ated with susceptibility to IDDM have been identified through the
Figure 4. Human hematolymphoid reconstitution at 16 weeks after transplantation. (A) In the BM, BRGS mice showed sustained multilineage engraftment of human
hematopoiesis at a level comparable to that in NOD-RG mice (F: BRGS female; Œ: NOD-RG female). (B) In the thymus, CD3 T cells were developed and their frequencies
were comparable in BRGS and NOD-RG mice. On FACS analysis, cells were differentiated into CD4 and CD8 single-positive T cells expressing the surface TCR- chain.
(C) In the spleen, CD10CD19CD20 mature B cells expressing surface Ig light chain 
 or  chain were present.
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development of congenic mouse strains. More than 20 Idd loci
have been identified. NOD mice display multiple aberrant immuno-
phenotypes, and introduction of these abnormalities into immuno-
deficient mouse lines by multiple backcrossing accelerated human
cell engraftment in xenotransplantation assays.11,14,15
In the current study, we present formal proof that under
disruption of T, B, and NK cells, NOD-specific Sirpa polymor-
phism could explain the efficient human cell engraftment in the
NOD strain. We replaced the Idd13 locus of C57BL/6-RG mice
with that of B6. The NOD-Idd13 mouse has the C57BL/6
background but is congenic for the NOD-derived 23cM segment of
chromosome 2 extending from microsatellite marker D2Mit274
through D2Mit343.43 In a previous study, we resolved the sequence
corresponding to the phenotype of support of human LTC-IC to a
region of 960 kilobases, within which coding regions of 14 genes
reside. Sirpa was the only gene within the Idd13 locus expressed in
BM stromal cells and macrophages and had coding sequence
polymorphism between the NOD and other strains.24 To determine
whether the efficient human cell engraftment in the NOD strains
was completely dependent on the NOD-type SIRPA polymor-
phism, we compared the engraftment efficiency of the BRGS
mouse with the NOD-RG mouse as a control, because in both
strains RAG and c genes are disrupted to disturb lymphoid cell
development. The NOD-RG strain displays the excellent human
cell engraftment comparable to the NOG/NSG strain21 in which the
SCID mutation instead of RAG-1 disruption is introduced. Our
data show that the reconstitution activity of human hematopoiesis
in BRGS mice is at least equal to that in NOD-RG mice in terms of
engraftment levels and multilineage reconstitution. Therefore,
replacement of the C57BL/6-Sirpa with the NOD-Sirpa is suffi-
cient for the C57BL/6-RG strain to gain the human cell engraft-
ment capability equal to the NOD-RG strain. NOD-SIRPA is able
to bind human CD47, signaling of which inhibits activation of host
macrophages to engulf human HSCs (Figure 1D), and therefore
this signaling might be able to inhibit xenograft rejection.24
The polymorphism of Sirpa could explain the strain-specific
trend toward human cell acceptability in xenotransplantation
experiments. There are 20 amino acid differences in the sequences
of Sirpa IgV domain between the NOD and B6 strains. Among
these, 5 amino acid residues are unique for NOD compared with
C57BL/6, BALB/c, ICR, and C3H. By testing their binding affinity
to human CD47 and their ability to support human LTC-IC, we
found that the xenograft capability–related NOD-specific polymor-
phism can be aggregated to a single location of polymorphism
(C.I., K.T., S.U., T.Y., K.I., J.K., T.M., K.A., The efficient
engraftment of human hematopoiesis in the BALB/c strain is
mounted by BALB/c-specific Sirpa polymorphism that enhances
binding affinity to human CD47, manuscript in preparation). In
Figure 5. Evaluation of self-renewal of human HSCs in the BRGS mouse model. (A) Change in frequency of human CD45 cells after transplantation. The level of human
CD45 cells was maintained at a high level until 24 weeks after transplantation (8 weeks, n  29; 16 weeks, n  17; and 24 weeks, n  4). (B) Change in the frequency of
human CD33 myeloid cells, B cells, T cells, and NK cells in the BM and spleen during the 24 weeks after transplantation (: 8 weeks; f: 16 weeks; and f: 24 weeks). Note
that the B-cell numbers gradually decreased and were compensated for by myeloid, T, and NK cells. (C) To test the self-renewal ability of human HSCs maintained in the first
recipient mice, 1  106 human CD45 cells were sorted from first-recipient mice and injected into second-recipient mice. Only female mice were used as recipients. After
another 8 weeks, 4 of 6 BRGS secondary recipients showed multilineage engraftment of human CD33, CD19, and CD3 cells. Representative FACS plots are shown.
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addition, we found recently that Balb/c mice also have another
polymorphism at the Sirpa IgV domain. Protein-binding assays
show that C57BL/6-SIRPA never binds to human CD47, but
Balb/c-SIRPA and NOD-SIRPA showed modest and very high
binding affinity, respectively, correctly reflecting their strain-
specific graft efficiencies.44 Furthermore, a recent study has shown
that the enforced expression of human SIRPA by a human BAC
transgene enables the 129;Balb/c.Rag1nullIl2rgnull mouse to engraft
human cells as efficiently as the NSG mouse.29 Therefore, in
xenograft models, the degree of SIRPA-CD47 interaction decided
by Sirpa polymorphism is one of the most critical factors to achieve
efficient human cell engraftment. Further study is required to
understand how the different binding affinity between these mouse
polymorphic SIRPAs and human CD47 is translated into cytoplas-
mic signaling that leads to respective efficiency for xenotransplan-
tation capabilities.
Figure 6. BRGS mice had CDC activity. Sera from
BRGS and C57BL/6-based mice showed CDC activity,
whereas none of the NOD-based strains did. Five mice
were analyzed in each strain. There were no statistical
differences in CDC activities among the C57BL/6-based
strains.
Figure 7. CDC activity of antibodies is evaluable in vivo in the BRGS xenogeneic model. (A) Experimental scheme of this experiment. Raji cells were injected into mice via
the tail vein. Ten days after the injection, either rituximab or control IgG2a antibody (200 g each) was injected IP daily for 1 week. (B) Frequencies of human CD45 Raji cells in
the BM of BRGS and NOD-RG mice with or without rituximab injection. A significant reduction of Raji cells was found only in BRGS mice injected with rituximab.
(C) Representative FACS plots of the BM cells of BRGS and NOD-RG mice after injection of rituximab or control IgG.
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Several recent studies have shown that, in xenograft models,
female mice somehow present significantly better reconstitution
than do male mice.38,39 It remains unclear whether sex-related
factors such as steroid hormones can affect the engraftment of
human HSCs. In the present study, the human cell chimerism
obtained in the BRGS strain was quite high, reaching  90% in
9 of 17 BRGS female mice, but none of the 13 NOD-RG female
mice achieved that level at 8 weeks after transplantation (Figure
2A). Furthermore, although BRGS male mice displayed lower
levels of human chimerism (approximately 45%), NOD-RG male
mice showed significantly lower levels than did NOD-RG female
mice, reaching only 20% of human cell chimerism in average on
our conditions (Figure 2A). As a result, the human cell chimerism
in BRGS male mice was significantly better than that in NOD-RG
male mice. Therefore, the BRGS mice showed a trend toward
higher levels of human chimerism in both the males and the
females. These results may suggest that unknown genetic abnormali-
ties antagonizing human cell reconstitution can exist outside of the
Idd13 locus in the NOD strain.
There remain many unknown factors that affect the efficiency of
human cell reconstitution in mouse xenotransplantation models.
For example, the BRGS model is capable of long-term, multilin-
eage human hematopoietic reconstitution, but human myeloid,
T, and NK cell reconstitution were significantly delayed compared
with the B-cell lineage (Figure 5B). This pattern of reconstitution is
commonly observed in other xenotransplantation models.40,41 Since
the introduction of human cytokines such as thrombopoietin and
membrane-bound SCF into humanized mouse models,45,46 myeloid
reconstitution has been accelerated, so the delay could have been
due to insufficient cross-reactivity of mouse cytokines with human
cytokine receptors. It is also possible that the mouse hematopoietic
microenvironment, including putative myeloid or lymphoid niches,
is not appropriate for human HSC development. The elucidation of
such unknown factors is necessary to develop further efficient
xenotransplantation models for future studies.
We have also shown herein the usefulness of the BRGS line in
testing the function of killing antibodies via CDC activity. Because
rituximab has both ADCC and CDC activity47 and because
NK cells, the major player for ADCC, are absent in efficient
xenograft models such as NOG,14 NSG,15 and NOD-RG20 mice, the
disappearance of Raji cells after rituximab injection in the BRGS
system must have been dependent largely on its CDC activity.
Selective cell depletion by killing antibodies should be very useful
in xenograft experiments, for example, in targeting cancer stem
cells,48 and in removing specific human cell component(s) from
reconstituted human hematolymphopoiesis in vivo. Therefore, the
BRGS humanized mouse model is applicable to future, more
sophisticated xenograft experiments.
In summary, in the present study, we selected NOD-type
polymorphic Sirpa from multiple abnormalities within the NOD
background and introduced it into the common C57BL6 mouse line
together with Rag2nullIl2rgnull mutations. The xenograft efficiency
of the BRGS line was equal to, or even better than, the NOD-RG
line, which is currently one of the best xenograft models. This
result formally proves that NOD-specific Sirpa polymorphism is
the genetic determinant of highly efficient xenograft activity in
NOD-based immunodeficient mouse models. Sparing other NOD-
specific abnormalities in this model also resulted in normalized
C5 function, which should help in future studies using CDC
activity of antibodies in vivo. The use of the BRGS line should also
save time in introducing other genes for further modification of the
line, keeping the high efficiency corresponding to the NOD-based
models without performing multiple backcrosses. Therefore, this
simplified mouse model should be very useful in future xenotrans-
plantation experiments using human cells.
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